Agonist
Back to library
GLP-1Subcutaneous

Semaglutide

Also known as: Ozempic · Wegovy · Rybelsus · Sema

Long-acting GLP-1 receptor agonist. Slows gastric emptying, suppresses glucagon, augments glucose-dependent insulin secretion, and acts on hypothalamic appetite circuits to reduce food intake.

At a glance

Half-life
6.9 days
Common route
Subcutaneous
Typical dose range
250–2,400mcg
Stability (reconstituted)
56days refrigerated

Best timing

Once weekly, same day each week. Time-of-day not critical given ~7-day half-life.

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2
  • History of pancreatitis
  • Severe gastroparesis
  • Pregnancy or planning pregnancy within 2 months

Watch symptoms

  • Nausea, vomiting, diarrhea (most common in first 8 weeks)
  • Severe abdominal pain radiating to back (pancreatitis signal)
  • Resting heart rate increase
  • Sulfur burps, reflux, early satiety to the point of malnutrition
  • Gallbladder pain, mood changes, hair shedding

Citations

The primary literature.

  1. 01Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)PubMed
  2. 02Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)PubMed

Related protocols

Stacks that use Semaglutide.

GLP-1 Starter

Twelve-week semaglutide titration for first-time GLP-1 users.

View protocol

Metabolic Reset

Sixteen-week 5-Amino-1MQ plus low-dose GLP-1 for insulin sensitivity and metabolic flexibility.

View protocol
Back to library